- About Us
- Advertise
- Contact Us
- CureToday.com
- CancerNetwork.com
- OncLive.com
- OncNursingNews.com
- Do Not Sell My Information
- Privacy
- Terms & Conditions
© 2022 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Leukemias | Clinical
Unmet Needs of AML and Advice for Community Oncologists
June 22, 2022
Courtney DiNardo, MD, concludes with discussing some challenges faced when treating patients with AML and shares some advice for community oncologists treating acute myeloid leukemia.
Safety Outcomes from the VIALE-A Trial
June 22, 2022
A review of the safety outcome data of venetoclax plus azacitidine from the VIALE-A trial.
Dose Management for Venetoclax plus Azacitidine
June 22, 2022
Dr Courtney DiNardo details the dosing recommendations for venetoclax plus azacitidine and the importance of bone marrow assessments.
The VIALE-A Trial: Venetoclax plus Azacitidine in AML Treatment
June 22, 2022
Dr Courtney DiNardo reviews the efficacy data from the VIALE-A trial and explains the rationale for combining venetoclax with azacitidine as a treatment option for patients with AML.
Treatment Options for Newly-Diagnosed AML
June 22, 2022
Courtney DiNardo, MD, describes how the treatment options for patients with newly diagnosed acute myeloid leukemia differs for patients under and over 60 years of age.
Quizartinib Combined with Chemotherapy Doubles OS Compared with Chemotherapy Alone in Patients with FLT3-ITD–Positive AML
June 13, 2022
Quizartinib with standard induction and consolidation chemotherapy followed by continued quizartinib monotherapy treatment led to significant improvement in overall survival in patients with newly diagnosed FLT3-ITD–positive acute myeloid leukemia.
FDA Approves Azacitidine for Newly Diagnosed Juvenile Myelomonocytic Leukemia
May 20, 2022
The FDA has granted approval to azacitidine for the treatment of pediatric patients with newly diagnosed juvenile myelomonocytic leukemia following positive phase 2 research.
Discussing the Role of CAR T-Cell Therapy for Patients with ALL
May 04, 2022
Hagop M. Kantarjian, MD, discusses the introduction of chimeric antigen receptor T cells and their impact on acute lymphoblastic leukemia.
Evolving Treatment Landscape of Acute Lymphocytic Leukemia
April 30, 2022
Hagop M. Kantarjian, MD, discusses how the treatment landscape of acute lymphocytic leukemia compares to what it used to be.
Matched Sibling Donor Transplant Improves 2-Year Overall Survival in R/R ALL
April 26, 2022
Retrospective data signal that transplant with a matched sibling donor may prolong survival over haploidentical stem cell transplant in patients with relapsed or refractory acute myeloid leukemia.